Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Immutep(LAG-3 specialist), belangrijke speler in een nieuw checkpoint voor blockbuster drugs
Volgen
Geloof is een mooi ding, het focussed je en haalt de twijfel weg. Helaas is dat ook de valkuil
ASX +5,56%, lijkt positief, maar die waren ook gisteren 12% gezakt, zegt dus nog niet veel.
weet niet of ik het kan vergelijken, maar in Nov.2020 lijkt er alleen op de dag van het PB een reactie te zijn geweest. op de dagen van settlement en issue geen grote uitslagen. Stelt mij wel gerust. PB op 19 nov.2020 Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development Timetable Settlement of the Placement is expected to occur on Tuesday, 24 November 2020 with the issue of New Shares expected to occur on Wednesday, 25 November 2020. vrijdag 16 nov. 2020 close 2,02 maandag 19 nov. 2020 close 1,90 22 nov. 1,90 23 nov. 1,89 24 nov. 1,91 25 nov. 1,87 27 nov. 1,90 30 nov. 1,97 07 dec. 2,09 10 dec. 5,69 24 dec. 2,94
Mooi speurwerk Dag Trader! Denk niet dat de koers grote sprongen gaat maken als de aangekondigde aandelen in omloop komen. Naar mijn mening al verwerkt in de koers. Ik verwacht tegen het einde van het jaar een hele mooie stijging van het aandeel. Uiteraard heb ik geen glazen bol...en kan ik ook volledig mis zijn. Maar de signalen zijn positief!
weer wat geleerd: Per Australian law, Immutep $IMMP shares were halted on the country’s stock exchange ahead of Monday’s announcement. endpts.com/lag-3-continues-generating...
het is wel even doorbijten met Immutep. Tijd voor wat herstel. Wat is daarvoor nodig? Een mooi PB, adviesverhoging of gewoon technisch herstel? Voorlopig is de uitgifte van de aandelen nog steeds niet volledig verwerkt in de markt/koers. Of straks een ommekeer? de avond is nog jong.
Voorlopig verkoop ik niet meer. Maandag een kort ritje naar 4,5 en bijgekocht op 4,28 en 4,44. GAK loopt wel op zo. Wanneer winst nemen is wel de vraag.
RT 4,04 , komende dagen spannend , houd de koers stand , gaan de extra aandelen invloed hebben. Of alleen in aus meer aandelen, 2e ronde?
3,93 bijgekocht Het mag terug omhoog
Ikkedike schreef op 29 juni 2021 20:55 :
3,93 bijgekocht
Het mag terug omhoog
Van mij ook, maar dat zal pas gebeuren als er wat goede berichten vanuit Australie komen. Anders zakken we weer richting 3,50 usd.
Dit is het transcript van medscape. Hello. I'm Dr Jeffrey Weber. I'm a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone Health in New York City. Today I'll be commenting on two studies on melanoma treatment presented at the oral sessions of this year's American Society of Clinical Oncology (ASCO) meeting. RELATIVITY-047 was a randomized study that included more than 700 patients with previously untreated melanoma. Patients were randomly assigned to receive either relatlimab (RELA), an antibody that blocks the lymphocyte activation gene 3 (LAG-3), plus nivolumab (NIVO) vs NIVO alone. The primary endpoint of this trial was investigator-called progression-free survival (PFS). The secondary endpoints were response rate and overall survival. This was a well-conducted, well-balanced, randomized phase 3 trial. All of the usual prognostic factors were well matched, including gender, age, performance status, serum LDH, tumor burden, and LAG-3 expression. Previous trials of second-line treatment have shown that a high LAG-3 expression in the tumor was associated with a better response. Overall, 75% of the patients in this study had LAG-3 in more than 1% of the tumor, presumably mostly on infiltrating immune cells, with 25% having LAG-3 in less than 1%, probably meaning that they were essentially LAG-3 negative. The median PFS in the RELA/NIVO combination arm was 10.1 months vs 4.6 months for NIVO alone, with a hazard ratio of 0.75 and a P value of .005. The 12-month PFS was 47% for the combo vs 36% for NIVO alone, clearly a winner for the combination. Benefit was seen in patients who were LAG-3 positive and also in those who were LAG-3 negative, which frankly is surprising. If you look at the PFS curves for LAG-3 expression greater than 1%, the median PFS for the RELA/NIVO group was 12 months vs 4.7 months for NIVO alone. For the minority of patients with a LAG-3 of less than 1%, PFS was around 4.8 months vs 2.8 months for NIVO alone — not quite as good, meaning the patients who were LAG-3 negative clearly had less impressive, less immunogenic, less inflamed tumors. LAG-3 is another checkpoint like PD-1, so that antibody will do better in the more inflamed tumors. The rate of grade 3/4 treatment-related, immune-related adverse events was about 18.9% for RELA/NIVO, compared with 9.7% for NIVO alone. There were three deaths in the RELA/NIVO group vs two deaths in the NIVO alone group. One death in the NIVO alone arm was related to myocarditis; three episodes of myocarditis, presumably not leading to death, occurred in the RELA/NIVO arm. The distribution of immune-related adverse events was typical, as you would expect with a slight increase in the combination arm, but again, I think quite tolerable. Bottom line: RELATIVITY-047 was the first phase 3 study to validate dual LAG-3 and PD-1 inhibition, and I think this was a clear winner. This provided clear evidence of greater activity in the RELA/NIVO combination than in NIVO alone. This presentation came right on the heels of another interesting study, presented by Rodabe Amaria, of neoadjuvant and adjuvant RELA/NIVO in patients with resectable stage III melanoma. A total of 30 patients received neoadjuvant RELA/NIVO, followed by resection, followed by adjuvant RELA/NIVO, something that has not been done before. The primary endpoints were the determination of the pathologic complete response (PCR) rate and the major pathologic response rates. Most of the 30 participants had an ECOG performance status of zero; the majority had stage IIIB or IIIC disease, with a sprinkling of patients with stage IIID or IV. Twenty-nine patients underwent surgery; one could not because of toxicity. The PCR rate was 59%, which is pretty darn impressive, with an additional 7% of patients at 90% PCR or better. A total of 66% of the patients had a major pathologic response rate. Those are impressive data. If you look at the overall radiographic response rate, it matches the PCR rate of 57%. I would agree with the investigator in that trial, however, that the radiologic response underestimates the pathologic response because the major response rate was 66%, but only 57% by radiologic assessment. Of the patients who had a major 90% or more pathologic complete response at 16 months of follow-up, no one has relapsed and the relapse rate in everyone else is a pretty healthy 60% at 16 months. Those are impressive data. In all, 26% of the patients had grade 3 immune-related adverse events in the adjuvant setting, with no significant dose-limiting toxicity in the patients who received two 4-week cycles of RELA/NIVO in the neoadjuvant setting. This is impressive data that sets up RELA/NIVO as a favored neoadjuvant regimen. It could replace ipilimumab/NIVO as the favored neoadjuvant immunotherapy regimen. This is Dr Jeffrey Weber. Please do contact me with questions or comments. Thank you for your attention.
www.immutep.com/files/content/investo... Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Kijkboek schreef op 6 juli 2021 03:44 :
www.immutep.com/files/content/investo... Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in
HNSCC
Dit is een mooi bericht. Immutep is op de goede weg. Jammer dat de koers in Australie niet uitbundiger reageert. Hopelijk is de neergaande trend gebroken na een gematigde positieve dag. Benieuwd hoe het op de beurs in de VS zal gaan met Immutep.
mooi! 0,545 AUD vertaalt naar $4,13, ik zeg 5% erbij en nu boven de 4$ blijven graag ;-) er komt vast nog meer nieuws aan deze maand...
Premarket gaat lekker. Ik ben benieuwd hoe snel we weer de 5 usd gaan aantikken. Dat moet lukken met dit pb.
Goudmijn64 schreef op 6 juli 2021 11:05 :
Premarket gaat lekker.
Ik ben benieuwd hoe snel we weer de 5 usd gaan aantikken.
Dat moet lukken met dit pb.
Bijzondere reactie in de USA... nadat ik de dag na de emissie uit paniek veel te vroeg verkocht à 4,15 ben ik weer volledig terug ingestapt op 3,85. Zal uiteraard weer veel te vroeg zijn, maar dit is toch gewoon prima en voor mij ook onverwacht nieuws!
Bijzonder inderdaad. In een ritje van 19 cent mijn GAK verlaagd. Was wel nodig:-) Er komen toch weer nieuwe aandelen aan op de Australische markt, het tweede deel van de emissie. Zal nog wel wat schommelingen teweeg brengen.
Helaas wordt men niet warm of koud van dit pb. Voor mij is het een bevestiging dat immutep op de goede weg zit. Dus we moeten geduld hebben.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
918,72
-0,64%
EUR/USD
1,0706
-0,31%
FTSE 100
8.146,86
-0,21%
Germany40^
18.004,30
-1,43%
Gold spot
2.332,68
0,00%
NY-Nasdaq Composite
17.688,88
+0,12%
Stijgers
Dalers